Isabelle Ray‐Coquard

Top papers

• Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

  Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, et al.·2019·New England Journal of Medicine
  ↗ 1,995OA
• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

  Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, et al.·2017·The Lancet Oncology
  ↗ 1,854
• Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

  Éric Pujade-Lauraine, Felix Hilpert, B. Weber, et al.·2014·Journal of Clinical Oncology
  ↗ 1,613OA
• Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

  Andreas du Bois, Alexander Reuß, Eric Pujade‐Lauraine, et al.·2009·Cancer
  ↗ 1,599OA
• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

  Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, et al.·2016·The Lancet Oncology
  ↗ 1,194OA
• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  Nicoletta Colombo, Cristiana Sessa, Andreas du Bois, et al.·2019·Annals of Oncology
  ↗ 1,146OA
• Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

  Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, et al.·2009·Cancer Research
  ↗ 790OA
• Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

  Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare, et al.·2009·Cancer Research
  ↗ 740
• Consensus meeting for the management of gastrointestinal stromal tumors
 Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

  Jean‐Yves Blay, Sylvie Bonvalot, Paolo G. Casali, et al.·2005·Annals of Oncology
  ↗ 721
• Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

  Thomas Bachelot, C. Bourgier, Claire Cropet, et al.·2012·Journal of Clinical Oncology
  ↗ 709OA
• Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

  Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, et al.·2008·Journal of Clinical Oncology
  ↗ 686OA
• Endometrial cancer

  Vicky Makker, Helen Mackay, Isabelle Ray‐Coquard, et al.·2021·Nature Reviews Disease Primers
  ↗ 666OA